Explore the impact of 3D models in drug discovery and how they enhance predictive insights in pre-clinical research.

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

Drug development is a costly, time-intensive and high-risk endeavour, with only two to three approvals for novel therapeutics in new drug classes per year eventually making it to market.

and limitations of preclinical models complicate the selection of effective therapies. This review presents a comprehensive framework for optimizing drug selection in neuro-oncology. We discuss ...

Cyclica’s drug discovery platform accelerates preclinical drug development by predicting the polypharmacological profile and medicinal properties of drug candidates. Developing effective and ...